학술논문

A phase III, open-label, randomized study of atezolizumab in combination with carboplatin plus paclitaxel plus bevacizumab compared with pemetrexed plus cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2020, 38 15, 2p. Supplement: S
Subject
Language
English
ISSN
15277755